Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10

Cytokine

Volumn 55, Issue 2, 2011, Pages 288-293

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Frascerra, Silvia ^a   Galetta, Fabio ^a   Franzoni, Ferdinando ^a   Corrado, Alda ^a   Miccoli, Mario ^a   Benvenga, Salvatore ^b   Paolicchi, Aldo ^a   Ferrannini, Ele ^a   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Chemokines; Chronic autoimmune thyroiditis; CXCL10; CXCL9; Hypothyroidism

Indexed keywords

CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LIOTHYRONINE; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; EUTHYROIDISM; FEMALE; HASHIMOTO DISEASE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; ORGAN BLOOD FLOW; ORGAN SIZE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TH1 CELL;

ADULT; CHEMOKINE CXCL10; CHEMOKINE CXCL9; FEMALE; GOITER, NODULAR; HUMANS; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; THYROID GLAND; THYROIDITIS, AUTOIMMUNE;

EID: 79959535759     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.04.022     Document Type: Article

References (38)

1. Liao F., Rabin R.L., Yannelli J.R., Koniaris L.G., Vanguri P., Farber J.M. Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995, 182:1301-1314.
2. Romagnani P., Annunziato F., Lasagni L., Lazzeri E., Beltrame C., Francalanci M., et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001, 107:53-63.
3. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Lang R., Borsatti A., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998, 187:129-134.
4. Wright T.M., Farber J.M. 5' regulatory region of a novel cytokine gene mediates selective activation by interferon gamma. J Exp Med 1991, 173:417-422.
5. Lacotte S., Brun S., Muller S., Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann NY Acad Sci 2009, 1173:310-317.
6. Melter M., Exeni A., Reinders M.E., Fang J.C., McMahon G., Ganz P., et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001, 104:2558-2564.
7. Hancock W.W., Lu B., Gao W., Csizmadia V., Faia K., King J.A., et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000, 192:1515-1520.
8. Hancock W.W., Gao W., Csizmadia V., Faia K.L., Shemmeri N., Luster A.D. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001, 193:975-980.
9. Simpson J.E., Newcombe J., Cuzner M.L., Woodroofe M.N. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2000, 26:133-142.
10. Goebeler M., Toksoy A., Spandau U., Engelhardt E., Bröcker E.B., Gillitzer R. The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol 1998, 184:89-95.
11. Patel D.D., Zachariah J.P., Whichard L.P. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001, 98:39-45.
12. Koga S., Auerbach M.B., Engeman T.M., Novick A.C., Toma H., Fairchild R.L. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig. J Immunol 1999, 163:4878-4885.
13. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Buonamano A., et al. High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004, 89:5496-5499.
14. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Paolicchi A., et al. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 2005, 152:171-177.
15. Kimura H., Kimura M., Rose N.R., Caturegli P. Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto's thyroiditis. Exp Mol Pathol 2004, 77:161-167.
16. Antonelli A., Ferrari S.M., Fallahi P., Frascerra S., Santini E., Franceschini S.S., et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009, 94:1803-1809.
17. Antonelli A., Ferrari S.M., Fallahi P., Ghiri E., Crescioli C., Romagnani P., et al. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine 2010, 50:260-267.
18. Antonelli A., Ferri C., Ferrari S.M., Colaci M., Sansonno D., Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 2009, 5:26-34.
19. Domberg J., Liu C., Papewalis C., Pfleger C., Xu K., Willenberg H.S., et al. Circulating chemokines in patients with autoimmune thyroid diseases. Horm Metab Res 2008, 40:416-421.
20. Shurin G.V., Yurkovetsky Z.R., Chatta G.S., Tourkova I.L., Shurin M.R., Lokshin A.E. Dynamic alteration of soluble serum biomarkers in healthy aging. Cytokine 2007, 39:123-129.
21. Wang S.H., Bretz J.D., Phelps E., Mezosi E., Arscott P.L., Utsugi S., et al. A unique combination of inflammatory cytokines enhances apoptosis of thyroid follicular cells and transform nondestructive to destructive thyroiditis in experimental autoimmune thyroiditis. J Immunol 2002, 168:2470-2474.
22. Caturegli P., Hejazi M., Suzuki K., Dohan O., Carrasco N., Kohn L.D., et al. Hypothyroidism in transgenic mice expressing IFN-gamma in the thyroid. Proc Natl Acad Sci USA 2000, 97:1719-1724.
23. Stassi G., De Maria R. Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat Rev Immunol 2002, 2:195-204.
24. Antonelli A., Fallahi P., Rotondi M., Ferrari S.M., Serio M., Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 2006, 93:1226-1231.
25. Antonelli A., Rotondi M., Fallahi P., Grosso M., Boni G., Ferrari S.M., et al. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 2007, 92:1485-1490.
26. Liu L., Callahan M.K., Huang D., Ransohoff R.M. Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol 2005, 68:149-181.
27. Proost P., Schutyser E., Menten P., Struyf S., Wuyts A., Opdenakker G., et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001, 98:3554-3561.
28. Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M., et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000, 164:6503-6508.
29. Sheikh A.M., Ochi H., Masuda J. Lysophosphatidylcholine inhibits T cell-specific CXC chemokines IP-10, MIG, and I-TAC expression induced by IFN-gamma in human endothelial cells. Ann NY Acad Sci 2001, 947:306-307.
30. Jinquan T., Jing C., Jacobi H.H., Reimert C.M., Millner A., Quan S., et al. CXCR3 expression and activation of eosinophils: role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma. J Immunol 2000, 165:1548-1556.
31. Salcedo R., Resau J.H., Halverson D., Hudson E.A., Dambach M., Powell D., et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J 2000, 14:2055-2064.
32. Trentin L., Agostini C., Facco M., Piazza F., Perin A., Siviero M., et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest 1999, 104:115-121.
33. Robledo M.M., Bartolome R.A., Longo N., Rodríguez-Frade J.M., Mellado M., Longo I., et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001, 276:45098-45105.
34. Jinquan T., Quan S., Jacobi H.H., Jing C., Millner A., Jensen B., et al. CXC chemokine receptor 3 expression on CD34(+) hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: chemotaxis and adhesion induced by its ligands, interferon gamma-inducible protein 10 and monokine induced by interferon gamma. Blood 2000, 96:230-1238.
35. Xia M.Q., Bacskai B.J., Knowles R.B., Qin S.X., Hyman B.T. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol 2000, 108:227-235.
36. Loetscher P., Pellegrino A., Gong J.H., Mattioli I., Loetscher M., Bardi G., et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001, 276:2986-2991.
37. McInnis K.A., Britain A., Lausch R.N., Oakes J.E. Synthesis of alpha-chemokines IP-10, I-TAC, and MIG are differentially regulated in human corneal keratocytes. Invest Ophthalmol Vis Sci 2005, 46:1668-1674.
38. Zhao D.X., Hu Y., Miller G.G., Luster A.D., Mitchell R.N., Libby P. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002, 169:1556-1560.